Prior Authorization Review Panel MCO Policy Submission
|
|
- Mildred Marcia Garrett
- 5 years ago
- Views:
Transcription
1 Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review. Plan: Aetna Better Health Submission Date: 11/01/2018 Policy Number: 0835 Policy Name: Hepatitis Screening Effective Date: Revision Date: Type of Submission Check all that apply: New Policy Revised Policy* Annual Review No Revisions *All revisions to the policy must be highlighted using track changes throughout the document. Please provide any clarifying information for the policy below: CPB 0835 Hepatitis Screening Clinical content was last revised 12/09/2016. Additional non-clinical updates were made by Corporate since the last PARP submission, as documented below. Revision and Update History since last PARP submission: 12/06/ This CPB has been updated with additional references. 09/27/2018 Next tentative scheduled review date by Corporate. Name of Authorized Individual (Please type or print): Signature of Authorized Individual: Dr. Bernard Lewin, M.D. Updated 12/06/2017
2 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 1 of 20 --> ( Hepatitis Screening Number: 0835 *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Policy Aetna considers hepatitis B virus (HBV) screening medically necessary for the following individuals: Current or former hemodialysis individuals Donors of blood, plasma, organs, tissues, or semen Household, needle-sharing, or sexual contacts of persons known to be HBV-positive Individuals born in Asia, Africa, and other geographic regions with a 2 % or higher prevalence of chronic HBV infection Infants born to HBV infected mothers Individuals with chronically elevated amino alanine transferase (ALT) or aspartate amino transferase (AST) of unknown etiology Individuals with HIV Injection drug users Men who have sexual contact with men Persons needing immunosuppressive therapy, including chemotherapy, immunosuppression related to organ transplantation, and immunosuppression for rheumatologic or gastroenterologic disorders Policy His tory Last Review 12/06/2017 Effective: 12/07/2012 Next Review: 09/27/2018 Review History Definitions A dditiona l In form at ion Clinical Policy Bulletin Notes
3 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 2 of 20 Persons who are the sources of blood or body fluids resulting in an exposure (e.g., needlestick, sexual assault) that might require post-exposure prophylaxis Pregnant women U.S. born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity (greater than or equal to 8 %), such as sub-saharan Africa, southeast and central Asia, and China. Aetna considers hepatitis C virus (HCV) screening medically necessary for the following individuals: Children born to HCV infected mothers Children from a region with high prevalence of HCV infection. Current or former hemodialysis individuals Individuals who received blood transfusions or organ transplants prior to July, 1992 or who received blood from a donor who later tested positive for HCV infection Individuals who received clotting factor concentrates produced before 1987 Individuals with HIV Individuals with persistently abnormal ALT levels Individuals with a recognized exposure such as health care workers, emergency medical personnel or public safety workers after needle sticks, sharps or mucosal exposures to HCV positive blood Injection drug users Present sexual partners of HCV-infected persons Aetna considers one-time testing without prior ascertainment of HCV risk medically necessary for persons born between 1945 to1965. See also: CPB Hepatitis A Vaccine (../1_99/0048.html), CPB Hepatitis B Vaccine (../400_499/0410.html).
4 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 3 of 20 Background Hepatitis refers to inflammation of the liver and also refers to a group of viral infections that affect the liver. The most common types are Hepatitis A, Hepatitis B, and Hepatitis C, although Hepatitis D and E viruses have also been identified. An estimated 4.4 million Americans are living with chronic hepatitis, the majority of whom do not know they are infected. Viral hepatitis is the leading cause of liver cancer and the most common reason for liver transplantation (CDC Division of Viral Hepatitis, 2012). Transmission of hepatitis A, which is caused by hepatitis A virus (HAV), occurs by the fecal-oral route through direct contact with an HAV-infected person or by ingestion of HAVcontaminated food or water. Foodborne or waterborne hepatitis A outbreaks are relatively uncommon in the United States, but food handlers with hepatitis A are frequently identified, and evaluation of the need for immunoprophylaxis and implementation of control measures are a considerable burden on public health resources. It is also notable that HAVcontaminated food may be the source of hepatitis A for an unknown proportion of persons whose source of infection is not identified (Fiore, 2004). Torner et al (2012) reported that although hepatitis A mass vaccination effectiveness is high, outbreaks continue to occur. They investigated the association between duration and characteristics of hepatitis A outbreaks reported between 1991 and An outbreak was defined as greater than or equal to 2 epidemiologically-linked cases with greater than or equal o 1 case laboratory-confirmed by detection of HA immunoglobulin M (IgM) antibodies. Between 1991 and 2007, 268 outbreaks (rate 2.45 per million persons-year) and 1,396 cases (rate 1.28 per 10(5) persons-year) were reported. Factors associated with shorter duration were time to intervention (OR = 0.96; 95 % confidence interval [CI]: 0.94 to 0.98) and school setting (OR = 0.39; 95 % CI: 0.16 to 0.92).
5 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 4 of 20 However, the authors also noted that in person-to-person transmission outbreaks, only time to intervention was associated with shorter outbreak duration (OR = 0.96; 95 % CI: 0.95 to 0.98). Torner et al concluded that making confirmed HA infections statutory reportable for clinical laboratories could diminish outbreak duration. Wiersma et al (2011) reported that most of the estimated 350 million people with chronic hepatitis B virus (HBV) live in resource-constrained settings and that up to 25 % of those persons will die prematurely of hepatocellular carcinoma or cirrhosis. They further state that an informal World Health Organization consultation of experts concluded that chronic HBV is a major public health problem in emerging nations, all HIV-infected persons should be screened for HBV infection, HIBV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance, and that standards for the management of chronic HBV infection should be adapted to resourceconstrained settings. Hepatitis B, which is caused by infection with the HBV, is found in highest concentrations in blood and in lower concentrations in other body fluids (e.g., semen, vaginal secretions, and wound exudates). HBV is efficiently transmitted by percutaneous or mucous membrane exposure to infectious blood or body fluids that contain blood. In adults, approximately half of newly acquired HBV infections are symptomatic, and approximately 1 % of reported cases result in acute liver failure and death. Risk for chronic infection is inversely related to age at infection, with approximately 90 % of infected infants and 3 0% of infected children aged less than 5 years becoming chronically infected, compared with 2 % to 6 % of adults. Among persons with chronic HBV infection, the risk for premature death from cirrhosis or hepatocellular carcinoma is 15 % to 25 %. The primary risk factors that have been associated with infection are unprotected sex with an infected partner, birth to an infected mother, unprotected sex
6 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 5 of 20 with more than one partner, men who have sex with other men, history of other sexually transmitted diseases, and illegal injection drug use (CDC Division of Viral Hepatitis, 2012). The United States Preventive Services Task Force (USPSTF) strongly recommends screening for HBV in pregnant women at their first prenatal visit. The USPSTF recommends against routinely screening the general asymptomatic population for chronic HBV infection (USPSTF, 2004). Weinbaum et al (2009) reported that early identification of persons with chronic HBV infection enables infected persons to receive necessary care to prevent or delay onset of liver disease, and enables the identification and vaccination of susceptible household contacts and sex partners, interrupting ongoing transmission. The authors emphasized that testing had been recommended previously to enable primary prevention of HBV infection among close contacts for pregnant women, household contacts and sex partners of HBV-infected persons, persons born in countries with hepatitis B surface antigen (HBsAg) prevalence of more than 8 %, persons who are the source of blood or body fluid exposures that might warrant post-exposure prophylaxis (e.g., needlestick injury to a healthcare worker or sexual assault), and to enable appropriate treatment for infants born to HBsAg-positive mothers and persons infected with human immunodeficiency virus. With the increasing availability of efficacious hepatitis B treatment, the CDC published updated recommendations for public health evaluation and management for chronically infected persons and their contacts which extended testing recommendations to include persons born in geographic regions with HBsAg prevalence of greater than 2 %, men who have sex with men, and injection drug users. The CDC, in collaboration with the New York City (NYC) Department of Health and Mental Hygiene (DOHMH), conducted a chronic HBV surveillance, selecting a random sample of newly reported cases and collecting more detailed information from the patients' clinicians. Analysis was
7 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 6 of 20 presented on 180 randomly selected HBV cases reported during June 2008 to November Approximately twothirds (67 %) of the patients were Asian, and the most commonly reported reason for HBV testing was the patient's birth country or race/ethnicity (27 %). In 70 % of cases, the clinician did not know of any patient risk factors and 62 % did not know their patient's hepatitis A vaccination status despite recommendations. Sixty-nine percent of clinicians stated that they counseled their patients about notifying close contacts about their infection, and 75 % counseled about transmission and prevention. This surveillance effort provided quantitative data on health disparities, illustrating that not all patients received recommended prevention and treatment services. In response to these findings, DOHMH now routinely distributes HBV patient education materials to populations in need (CDC, 2012). HCV infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million persons chronically infected. Sixty to 70 % of persons newly infected with HCV typically are asymptomatic or have a mild clinical illness. HCV RNA can be detected in blood within 1 to 3 weeks after exposure, the average time from exposure to antibody to HCV (anti-hcv) seroconversion is 8 to 9 weeks, and anti-hcv can be detected in greater than 97 % of persons by 6 months after exposure. Chronic HCV infection develops in 70 % to 85 % of HCV-infected persons and 60 % to 70 % of chronically infected persons have evidence of active liver disease. Although the majority of infected persons may not be aware of their infection, infected persons serve as a source of transmission to others and are at risk for chronic liver disease or other HCV-related chronic diseases decades after infection occurs. HCV is most efficiently transmitted through large or repeated percutaneous exposure to infected blood (e.g., through transfusion of blood from unscreened donors or through use of injecting drugs). Although much less frequent, occupational, perinatal, and sexual exposures also can result in transmission of HCV (CDC Division of Viral Hepatitis, 2012).
8 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 7 of 20 Denniston et al (2012) discussed that many persons infected with hepatitis C virus (HCV) are unknown to the healthcare system because they may be asymptomatic for years, have not been tested for HCV infection, and only seek medical care when they develop liver-related complications. The authors analyzed data from persons who tested positive for past or current HCV infection during participation in the National Health and Nutrition Examination Survey (NHANES) during the years 2001 through They conducted a follow-up survey 6 months after examination to determine (i) how many participants testing positive for HCV infection were aware of their HCV status before being notified by NHANES, (ii) what actions participants took after becoming aware of their first positive test, and (iii) participants' knowledge about hepatitis C. Of the 30,140 participants tested, 393 (1.3 %) had evidence of past or current HCV infection and 170 (43 %) could be contacted during the follow-up survey and interviewed. Only 49.7 % were aware of their positive HCV infection status before being notified by NHANES and only 3.7 % of these respondents reported that they had first been tested for HCV because they or their doctor thought they were at risk for infection. The study results showed that, overall, 85.4 % had heard of hepatitis C and that correct responses to questions about hepatitis C were higher among persons 40 to 59 years of age, white non-hispanics, and respondents who saw a physician after their first positive HCV test. Eighty percent of respondents indicated they had seen a doctor about their first positive HCV test result. The investigators concluded that these data indicated that fewer than 50 % of those infected with HCV may be aware of their infection. The findings suggest that more intensive efforts are needed to identify and test persons at risk for HCV infection. Smith et al (2012) reported that many of the 2.7 to 3.9 million persons living with HCV infection, an increasing cause of morbidity and mortality in the United States, are unaware they are infected and do not receive care (e.g., education,
9 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 8 of 20 counseling, and medical monitoring) and treatment. The CDC estimates that although persons born between 1945 to1965 comprise an estimated 27 % of the population, they account for approximately three-fourths of all HCV infections in the United States, 73 % of HCV-associated mortality, and are at greatest risk for hepatocellular carcinoma and other HCVrelated liver disease. The CDC is augmenting previous recommendations for HCV testing to recommend one-time testing without prior ascertainment of HCV risk for persons born during 1945 to1965. These recommendations do not replace previous guidelines for HCV testing that are based on known risk factors and clinical indications, but rather define an additional target population for testing: persons born during 1945 to The CDC developed these recommendations with the assistance of a work group representing diverse expertise and perspectives. The recommendations are informed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, an approach that provides guidance and tools to define the research questions, conduct the systematic review, assess the overall quality of the evidence, and determine the strength of the recommendations. The United States Centers for Disease Control currently has in place recommendations regarding screening for both hepatitis B and hepatitis C. The USPSTF (Moyer, 2013) recommended screening for HCV infection in persons at high risk for infection. The USPSTF also recommended offering 1-time screening for HCV infection to adults born between 1945 and (B recommendation). The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) s practice guidelines on Diagnosis and management of hepatitis C infection in infants, children, and adolescents (Mack et al, 2012) noted that children from a region with high prevalence of HCV infection as well as present sexual partners of HCV-infected persons should be screened for HCV infection.
10 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 9 of 20 Updated USPSTF recommendations on screening for HBV were published in May, These recommendations are based on current evidence on the benefits and harms of antiviral therapy, the benefits of education on behavior change counseling, and the association between improvements in intermediate and clinical outcomes after antiviral therapy. The recommendation updates are focused on high-risk populations and reflect current evidence the USPSTF identified that HBV vaccination is effective for decreasing disease acquisition in high-risk populations. The risk for HBV infection varies substantially by country of origin in foreign-born persons in the United States (US), particularly persons born in countries with a prevalence of HBV infection of 2% or greater. The recommendations further note that lack of vaccination in infancy in US-born persons with parents from a country or region with high prevalence ( 8%). including sub-saharan Africa, central and southeast Asia, and China, is an important risk factor (USPSTF, 2014). The Centers for Medicare and Medicaid (CMS) issued a National Coverage Determination on June 2, 2014 stating that "the evidence is adequate to conclude that screening for HCV, in accord with the USPSTF recommendations, is reasonable and necesasry for the prevention or early detection of an illness or disability and is appropriate for individuals entitled to benefits under Part A or erolled under Part B." Therefore, CMS will cover screening for HCV for beneficiaries who are adults at high risk for HCV infection, high risk being defined as a current or past history of illicit injection drug use or a history of receiving blood transfusion prior to 1992, CMS will also cover a single screening test for adults who do not meet the CMS definition of high risk, but who were born from 1945 through Hwang et al (2015) provided a revised opinion on Hepatitis B virus screening for patients with cancer before therapy based on the American Society of Clinical Oncology (ASCO) panel s consensus opinion in the context of an evolving database. This
11 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 10 of 20 updated provisional clinical opinion introduced a risk-adaptive strategy to identify and treat patients with HBV infection to reduce their risk of HBV re-activation. Medical providers should screen by testing patients for HBV infection before starting anti-cd20 therapy or hematopoietic cell transplantation. Providers should also screen patients with risk factors for HBV infection. Screening should include both hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-hbc), because re-activation can occur in patients who are HBsAg positive/anti-hbc positive or HBsAg negative/anti-hbc positive. Either total anti-hbc or anti-hbc immunoglobulin G (not immunoglobulin M) test should be used. Clinicians should start anti-viral therapy for HBsAgpositive/anti-HBc positive patients before or contemporaneously with cancer therapy and monitor HBsAgnegative/anti-HBc positive patients for re-activation with HBV DNA and ALT levels, promptly starting anti-virals if reactivation occurs. Clinicians can initiate anti-virals for HBsAgnegative/anti-HBc positive patients anticipating cancer therapies associated with a high risk of re-activation, or they can monitor HBV DNA and ALT levels and initiate on-demand anti-virals. For patients who neither have HBV risk factors nor anticipate cancer therapy associated with a high risk of reactivation, current evidence does not support HBV screening before initiation of cancer therapy. The ASCO panel suggests HBV screening for patients with cancer and HBV risk factors before initiation of systemic cancer therapy. Risk groups include the following: Persons born in countries and regions with prevalence of HBV infection greater than or equal to 2 % US-born persons not vaccinated as infants whose parents were born in regions with high prevalence of HBV infection (greater than or equal to 8 %; e.g., sub- Saharan Africa, southeast and central Asia) HIV-positive persons
12 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 11 of 20 Injection drug users Men who have sex with men Those with household or sexual contact with persons with HBV infection The American Gastroenterological Association (AGA) s guideline on The prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy (Reddy et al, 2015) recommended screening for HBV (HBsAg and anti- HBc, followed by a sensitive HBV DNA test if positive) in patients at moderate or high risk who will undergo immunosuppressive drug therapy. The AGA recommended against routinely screening for HBV in patients who will undergo immunosuppressive drug therapy and are at low risk. The Centers for Medicare and Medicaid Services (CMS, 2016) has determined that a screening test is covered for asymptomatic, nonpregnant adolescents and adults at high risk for HBV infection. "High risk" is defined as persons born in countries and regions with a high prevalence of HBV infection (i.e., 2%), U.S.-born persons not vaccinated as infants whose parents were born in regions with a very high prevalence of HBV infection (i.e., 8%), HIV-positive persons, men who have sex with men, injection drug users, household contacts or sexual partners of persons with HBV infection. In addition, CMS has determined that repeated screening would be appropriate annually only for beneficiaries with continued high risk (i.e., men who have sex with men, injection drug users, household contacts or sexual partners of persons with HBV infection) who do not receive hepatitis B vaccination. CMS (2016) has stated that a screening test at the first prenatal visit is covered for pregnant women and then rescreening at time of delivery for those with new or continuing risk factors. In addition, CMS has determined that screening during the first prenatal visit would be appropriate for each
13 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 12 of 20 pregnancy, regardless of previous hepatitis B vaccination or previous negative hepatitis B surface antigen (HBsAg) test results. A ppendix Geographic regions with an HBsAg prevalence 2% * Region Countries Africa Asia Australia and South Pacific Middle East Eastern Europe Western Europe North America Mexico and All All All except Australia and New Zealand All except Cyprus and Israel All except Hungary Malta, Spain, and indigenous populations in Greenland Alaska natives and indigenous populations in northern Canada Guatemala and Honduras Central America South America Caribbean Ecuador, Guyana, Suriname, Venezuela, and Amazonian areas of Bolivia, Brazil, Colombia, and Peru Antigua and Barbuda, Dominica, Grenada, Haiti, Jamaica, St. Kitts and Nevis, St. Lucia, and Turks and Caicos Islands Adapted from Weinbaum et al, 2008.
14 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 13 of 20 * Estimates of prevalence of HBsAg, a marker of chronic hepatitis B virus infection, are based on limited data and might not reflect current prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prevalence might vary within countries by subpopulation and locality. The regions with the highest prevalence (>5%) are sub- Saharan Africa and central and southeast Asia. A complete list of countries in each region is available at the CDC s Vaccines. Medicines. Advice webpage. Asia includes three regions: Southeast Asia, east Asia, and northern Asia. CPT Codes / HCPCS Codes / ICD-10 Codes Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+": Code Code Description Hepatitis B Virus (HBV) screening: CPT codes covered if selection criteria are met: Hepatitis B core antibody (HBcAb); total IgM antibody Hepatitis B surface antibody (HBsAb) Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) hepatitis B surface antigen (HBsAg) neutralization HCPCS codes covered if selection criteria are met:
15 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 14 of 20 Code Code Description G0499 Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag) followed by a neutralizing confirmatory test for initially reactive results, and antibodies to hbsag (anti-hbs) and hepatitis b core antigen (anti-hbc) ICD-10 codes covered if selection criteria are met: B20 Human immunodeficiency virus [HIV] disease B97.35 Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere F Opioid related disorders [injecting drug users] F11.99 F F13.99 F Sedative, hypnotic, or anxiolytic related disorders [injecting drug users] Cocaine related disorders [injecting drug users] F14.99 F F15.99 O O16.9 O O29.93 Other stimulant related disorders [injecting drug users] Edema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium Other maternal disorders predominantly related to pregnancy R74.0 Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH][ALT or AST] Z20.2 Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission Z20.5 Contact with and (suspected) exposure to viral hepatitis
16 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 15 of 20 Code Code Description Z20.6 Contact with and (suspected) exposure to human immunodeficiency virus [HIV] Z21 Asymptomatic human immunodeficiency virus [HIV] infection status Z22.4 Carrier of infections with a predominantly sexual mode of transmission Z Carrier of viral hepatitis Z22.59 Z Encounter for supervision of normal pregnancy Z34.93 Z51.11 Encounter for antineoplastic chemotherapy Z High-risk sexual behavior Z72.53 Z Transplanted organ and tissue status Z94.9 Z99.2 Dependence on renal dialysis Hepatitis C Virus (HCV) screening: CPT codes covered if selection criteria are met: Hepatitis C antibody Confirmatory test (eg, immunoblot) HCPCS codes covered if selection criteria are met: G0472 Hepatitis C antibody screening for individual at high risk and other coverage indication(s) ICD-10 codes covered if selection criteria are met (not all inclusive): B20 Human immunodeficiency virus [HIV] disease B97.35 Human immunodeficiency virus, type II [HIV-2]
17 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 16 of 20 Code Code Description D65 - Coagulation defects, purpura and other D69.9 hemorrhagic conditions F Opioid related disorders [injecting drug users] F11.99 F F13.99 F Sedative, hypnotic, or anxiolytic related disorders [injecting drug users] Cocaine related disorders [injecting drug users] F14.99 F F15.99 T80.61X+ Other stimulant related disorders [injecting drug users] Other serum reaction due to administration of blood products [Blood transfusion, without reported diagnosis] Z20.5 Contact with and (suspected) exposure to viral hepatitis Z Carrier of viral hepatitis Z22.59 Z Transplanted organ or tissue status Z94.9 Z99.2 Dependence on renal dialysis The above policy is based on the following references: 1. Fiore AE. Hepatitis A transmitted by food. Clinical Infectious Diseases. 2004;38: US Preventive Services Task Force (USPSTF). Screening for hepatitis B infection, topic page. Rockville, MD: U.S. Preventive Services Task Force; Available at:
18 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 17 of 20 Accessed August 28, Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S35-S Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: Expert panel consensus. Liver Int. 2011;31(6): Centers for Disease Control and Prevention (CDC). Surveillance for chronic hepatitis B virus infection - New York City, June 2008-November MMWR Morb Mortal Wkly Rep. 2012;61(1): CDC Division of Viral Hepatitis. Viral Hepatitis. Atlanta, GA: Centers for Disease Control and Prevention; Available at: Accessed August 23, Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey Hepatology. 2012;55 (6): Smith BD, Morgan RL, Beckett GA. Recommendations for the identification of chronic hepatitis C virus infection among persons born during MMWR Recomm Rep. 2012;61(RR-4): Torner N, Broner S, Martinez A, et al. Factors associated to duration of hepatitis a outbreaks: Implications for control. PLoS One. 2012;7(2):e Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54(6):
19 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 18 of Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5): Weinbaum CM, Williams I, Mast EE, et al. Centers for Disease Control and Prevention recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recommendations Report. 2008;57(RR-8): US Preventive Services Task Force (USPSTF). Screening for hepatitis B virus infection in nonpregnanat adolescents and adults: US Preventive Services Task Force recommendation statement. Rockville, MD: USPSTF;2014. Available at: Accessed June 2, Center for Medicare & Medicaid Services (CMS). Screening for hepatitis C virus (HCV) in adults. Decision Memorandum # CAG-00436N. Baltimore, MD: CMS; June 2, Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33(19): Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1): van Rooijen M, Heijman T, de Vrieze N, et al. Earlier detection of hepatitis C virus infection through routine hepatitis C virus antibody screening of human immunodeficiency virus-positive men who have sex with men attending a sexually transmitted infection outpatient clinic: A longitudinal study. Sex Transm Dis. 2016;43(9):
20 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 19 of Centers for Medicare & Medicaid Services (CMS). Screening for hepatitis B virus (HBV) infection. Decision Memorandum #CAG-00447N. Baltimore, MD: CMS; September 28, Centers for Disease Control and Prevention. Vaccines. Medicines. Advice. Available at: Accessed august 16, Brady JE, Liffmann DK, Yartel A, et al. Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study. Hepatology. 2017;65(1): Federman AD, Kil N, Kannry J, et al. An electronic health record-based intervention to promote hepatitis C virus testing among adults born between 1945 and 1965: A cluster-randomized trial. Med Care. 2017;55 (6):
21 Hepatitis Screening - Medical Clinical Policy Bulletins Aetna Page 20 of 20 Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change. Copyright Aetna Inc.
22 AETNA BETTER HEALTH OF PENNSYLVANIA Amendment to Aetna Clinical Policy Bulletin Number: 0835 Hepatitis Screening Screening for Hepatitis B and C do not require prior authorization for the Pennsylvania Medical Assistance plan. Updated 12/06/2017
U.S. Preventive Services Task Force
BONUS DIGITAL CONTENT U.S. Preventive Services Task Force Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Recommendation Statement As published by the U.S. Preventive Services
More informationPage 1 of 6. Hepatitis B Virus (HBV) PRESENTATION RECOMMENDED IMMMUNOSUPRESSIVE TREATMENT TEST RESULTS. Obtain baseline HBV DNA level
Hepatitis B Virus (HBV) PRESENTATION Medical history: Previous history of HBV On anti-hbv medications Hepatitis Screening and Management HBV and HCV Risk factors associated with HBV infection: Born in
More informationHepatitis B and C Basics
Hepatitis B and C Basics What is the liver? The liver is the largest internal organ that performs many important functions. Stores nutrients and vitamins Fights infection Stores energy Removes harmful
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationHepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationHepatitis B Vaccination and Prevention. Angela M. Jo, MD, MSHS
Hepatitis B Vaccination and Prevention Angela M. Jo, MD, MSHS What is Hepatitis B? A virus that lives in blood and other bodily fluids An infectious disease that causes liver disease and cancer 100 x more
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationAPPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College
APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationHepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages
2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,
More informationHepatitis B and C Overview, Outbreaks, and Recommendations. Viral Hepatitis Language. Types of Viral Hepatitis 7/1/2013
Hepatitis B and C Overview, Outbreaks, and Recommendations Elizabeth Lawlor, MS Healthy Kansans living in safe and sustainable environments. Viral Hepatitis Language Acute infection is when the infection
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #400 (NQF 3059): One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY
More informationALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES
ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis
More informationkeyword: hepatitis Hepatitis
www.bpac.org.nz keyword: hepatitis Hepatitis Key reviewers: Dr Susan Taylor, Microbiologist, Diagnostic Medlab, Auckland Dr Tim Blackmore, Infectious Diseases Physician and Microbiologist, Wellington Hospital,
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationEpidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
More informationViral Hepatitis in Ireland, 2005
Viral Hepatitis in Ireland, 25 Key Points Hepatitis A incidence remained low, with 56 cases notified in 25 The number of hepatitis B notifications continued to increase with 95 cases reported in 25, compared
More informationViral Hepatitis. Background
Viral Hepatitis Background Hepatitis or inflammation of the liver can be caused by infectious and noninfectious problems. Infectious etiologies include viruses, bacteria, fungi and parasites. Noninfectious
More informationHepatitis B at a Glance
Return completed form, preferably within 30 days of U.S. date of arrival, to address on reverse side of this form. Review overseas medical exam if available and document immunization dates. Indicate if
More informationHIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED
HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationElimination of Perinatal Hepatitis B Transmission
Elimination of Perinatal Hepatitis B Transmission Trudy V. Murphy, MD Division of Viral Hepatitis NCHHSTP, CDC December 19, 2013 Hep B United and WHIAAPI Webinar Background q Hepatitis B is an infection
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationRecommendations for Hepatitis C Screening
Hepatitis C Online PDF created June 16, 2018, 9:14 am Recommendations for Hepatitis C Screening This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationSeroprevalence of Hepatitis B Surface Antigen (HBsAg) Among Patients at a Tertiary Care Hospital in Mumbai, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 4 (2017) pp. 722-726 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.604.088
More informationTaken From VBA s Adjudication Procedure Manual Section on Hepatitis
Taken From VBA s Adjudication Procedure Manual Section on Hepatitis M21-1, Part III, Subpart iv, 4.I.2 Updated January 11, 2017 2. Hepatitis and Other Liver Disabilities Introduction Change Date January
More informationTo provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids.
TITLE/DESCRIPTION: MANAGEMENT OF OCCUPATIONAL EXPOSURE TO HBV, HCV, and HIV INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All GCC Countries GULF COOPERATION COUNCIL
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHow does HBV affect the liver?
Hepatitis B Why is the liver important? Your liver is a vital organ that performs many essential functions. It s the largest solid organ in the body and is located under your rib cage on the upper right
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
8 April 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH PROGRAMME SUBCOMMITTEE Sixty-fourth session Brazzaville, Republic of Congo, 9 11 June 2014 Provisional agenda item 6 VIRAL HEPATITIS: SITUATION
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationChapter 5 Serology Testing
Chapter 5 Serology Testing 49 50 This page intentionally left blank. Diagnostic Tests for Hepatitis B Virus (HBV) Diagnosis of HBV infection (acute vs. chronic) is based on clinical, laboratory, and epidemiologic
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
5 November 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-fourth session Cotonou, Republic of Benin, 3 7 November 2014 Provisional agenda item 11 VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationTime to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention
Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and
More informationObstetric Complications in HIV-Infected Women. Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School
Obstetric Complications in HIV-Infected Women Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School Obstetric Complications and HIV Obstetric complications are not increased in
More informationNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States
More informationINITIAL EVALUATION AND MANAGEMENT FOLLOWING EXPOSURE TO BLOOD OR BODY FLUIDS
Page 1 of 11 Original Date of Issue: June 1991 Reviewed 2/96 5/97 11/98 11/99 5/01 5/02 12/05 Revised 9/95 5/97 5/00 7/02 3/06 6/08 6/10 The following are the procedures to be followed when a person sustains
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Volume 12, Issue 4 December, 2013 Overview Prevention of Perinatal Hepatitis B Transmission Perinatal transmission of hepatitis B virus (HBV) is preventable through universal
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationA Provider s Guide to Sustainability and Reimbursement of HIV Testing in Florida Health Care Facilities
A Provider s Guide to Sustainability and Reimbursement of HIV Testing in Florida Health Care Facilities April 2011 www.fcaetc.org www.floridaaids.org USF Center for HIV Education and Research Publication
More informationChallenges for viral hepatitis prevention in Latin American
Challenges for viral hepatitis prevention in Latin American One in three people on earth has been exposed to hepatitis B or C viruses (HBV and HCV); HBV and HCV are responsible for 57% of cirrhosis and
More informationPerinatal Hepatitis b Prevention
Perinatal Hepatitis b Prevention Purpose 2 The primary goal of the Perinatal Hepatitis b Prevention Program (PHBPP) is to identify all pregnant women who are infected with hepatitis b and prevent perinatal
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationC 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官
C 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官 HCV:Structure and Classification Unclassified virus, Member of the flavivirus family (other members yellow fever and dengue) Enveloped single stranded RNA virus Humans
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationStrategies to Address HCV
Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The
More informationHepatitis. Epidemiology and Prevention of Viral Hepatitis A, B, and C:
Epidemiology and Prevention of Viral Hepatitis A, B, and C: An Overview Andrea L. Cox, M.D., Ph.D. The Viral Hepatitis Center The Johns Hopkins University Hepatitis Inflammation of the liver Can be caused
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationPERINATAL HEPATITIS B
PERINATAL HEPATITIS B A Prevention Strategy Douglas County Health Department, Omaha, NE Why Prevention is Important About 1.25 million people in the U.S. have chronic hepatitis B infection Hepatitis B
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationHepatitis and pregnancy
Hepatitis and pregnancy Pierre-Jean Malè MD Training Course in Reproductive Health Research WHO Geneva 2008 26.02.2008 Liver disease and pregnancy: three possible etiologic relationship the patient has
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationInfection/Disease Control HEPATITIS CONTROL PROGRAM
OPERATING PROCEDURE NO. 153-29 Florida State Hospital Chattahoochee, Florida July 8, 2009 Infection/Disease Control HEPATITIS CONTROL PROGRAM 1. Purpose: To establish consistent surveillance, reporting,
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationRegional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 04, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 34 (EW 34), from 23 August to 29 August, 20 countries reported
More informationSUBJECT: Hepatitis C Virus (HCV) Counseling/Education, Testing, Referral, and Partner Notification
SUBJECT: Hepatitis C Virus (HCV) Counseling/Education, Testing, Referral, and Partner Notification Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States.
More informationCarrier state and chronic infection state. At-risk populations
John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology and Nutrition Carrier state and chronic infection state -
More informationInternist Diagnosis and Management of Chronic Hepatitis B Virus Infection
UPDATE IN OFFICE MANAGEMENT Internist Diagnosis and Management of Chronic Hepatitis B Virus Infection Brian J. McMahon, MD, a Joan Block, RN, BSN, b Barbara Haber, MD, c Thomas London, MD, d James A. McHugh,
More informationLifetime risk of infection >60% Early childhood infections common
Hepatitis Community Medicine HBV Public health sig HBV is 100 times more infectious than HIV. >350 million chronically infected worldwide. >1 million people die annually of HBV- related chronic liver disease.
More informationEXPOSURE (HIV/HEPATITIS) BLOOD & BODY FLUIDS
Page(s): 1 of 11 PURPOSE To set a standardized procedure to ensure that employees are evaluated in a consistent and timely manner.. POLICY A. The treatment of Team Member exposure to bloodborne pathogens
More informationViral Hepatitis B and C in North African Countries
Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral
More informationDigestive & Liver Disease Wellness
Digestive & Liver Disease Wellness Colorectal Cancer Screening & Prevention According to the American Cancer Society, this year 136,830 people in the U.S. According will be to diagnosed the American with
More informationRoutine HIV Testing in Healthcare Settings: Reimbursement & Sustainability Updated October, 2017
Routine HIV Testing in Healthcare Settings: Reimbursement & Sustainability Updated October, 2017 Overview Importance of routine testing Current recommendations for testing Reimbursement for HIV counseling
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationCoding for Preventive Services A Guide for HIV Providers
Coding for Preventive Services A Guide for HIV Providers Jessie Murphy, MPH and Michelle Cataldo, LCSW, April 2016 Implementation of the Patient Protection and Affordable Care Act and other regulatory
More informationRegional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (December 1, 2009-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More information*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a
*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a GDPH epidemiologist 404-657-2588, 8-5 pm M-F for current
More informationRegional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (March 15, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More information